JP2019522486A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019522486A5 JP2019522486A5 JP2019501623A JP2019501623A JP2019522486A5 JP 2019522486 A5 JP2019522486 A5 JP 2019522486A5 JP 2019501623 A JP2019501623 A JP 2019501623A JP 2019501623 A JP2019501623 A JP 2019501623A JP 2019522486 A5 JP2019522486 A5 JP 2019522486A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- scaffold
- cells
- item
- slb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 157
- 238000000034 method Methods 0.000 claims description 93
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 36
- 230000003213 activating effect Effects 0.000 claims description 32
- 230000000139 costimulatory effect Effects 0.000 claims description 29
- 239000000232 Lipid Bilayer Substances 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 18
- 239000000377 silicon dioxide Substances 0.000 claims description 18
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 230000010001 cellular homeostasis Effects 0.000 claims description 17
- 239000000523 sample Substances 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 8
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 8
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 8
- 239000002131 composite material Substances 0.000 claims description 8
- 230000013632 homeostatic process Effects 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 7
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 7
- 239000012472 biological sample Substances 0.000 claims description 7
- 102000019034 Chemokines Human genes 0.000 claims description 6
- 108010012236 Chemokines Proteins 0.000 claims description 6
- 102000008070 Interferon-gamma Human genes 0.000 claims description 5
- 108010074328 Interferon-gamma Proteins 0.000 claims description 5
- 229960003130 interferon gamma Drugs 0.000 claims description 5
- 210000003289 regulatory T cell Anatomy 0.000 claims description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 230000000903 blocking effect Effects 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 3
- 239000002458 cell surface marker Substances 0.000 claims description 3
- 238000012412 chemical coupling Methods 0.000 claims description 3
- 230000008595 infiltration Effects 0.000 claims description 3
- 238000001764 infiltration Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 108091006020 Fc-tagged proteins Proteins 0.000 claims description 2
- 102100027581 Forkhead box protein P3 Human genes 0.000 claims description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 claims description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 claims description 2
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 claims description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims description 2
- 102100033467 L-selectin Human genes 0.000 claims description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims description 2
- 230000006044 T cell activation Effects 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012636 effector Substances 0.000 claims description 2
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 230000010354 integration Effects 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims 3
- 210000000581 natural killer T-cell Anatomy 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims 1
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102000017578 LAG3 Human genes 0.000 claims 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 1
- 230000020385 T cell costimulation Effects 0.000 claims 1
- 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 claims 1
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 claims 1
- 230000001483 mobilizing effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 description 12
- -1 IL13Rα Proteins 0.000 description 9
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 101000633786 Homo sapiens SLAM family member 6 Proteins 0.000 description 4
- 102100029197 SLAM family member 6 Human genes 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102100027207 CD27 antigen Human genes 0.000 description 3
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 description 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108090000172 Interleukin-15 Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 3
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 239000002619 cytotoxin Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 2
- SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 2
- NEZDNQCXEZDCBI-UHFFFAOYSA-N 2-azaniumylethyl 2,3-di(tetradecanoyloxy)propyl phosphate Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCC NEZDNQCXEZDCBI-UHFFFAOYSA-N 0.000 description 2
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 208000029483 Acquired immunodeficiency Diseases 0.000 description 2
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- 102100038077 CD226 antigen Human genes 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 101710112752 Cytotoxin Proteins 0.000 description 2
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101001068136 Homo sapiens Hepatitis A virus cellular receptor 1 Proteins 0.000 description 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 description 2
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102100038082 Natural killer cell receptor 2B4 Human genes 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 102100029198 SLAM family member 7 Human genes 0.000 description 2
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 description 2
- 102100033447 T-lymphocyte surface antigen Ly-9 Human genes 0.000 description 2
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FFILOTSTFMXQJC-QCFYAKGBSA-N (2r,4r,5s,6s)-2-[3-[(2s,3s,4r,6s)-6-[(2s,3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-[(2r,3s,4r,5r,6r)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(e)-3-hydroxy-2-(octadecanoylamino)octadec-4-enoxy]oxan-3-yl]oxy-3-hy Chemical compound O[C@@H]1[C@@H](O)[C@H](OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO[C@]2(O[C@@H]([C@@H](N)[C@H](O)C2)C(O)C(O)CO)C(O)=O)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 FFILOTSTFMXQJC-QCFYAKGBSA-N 0.000 description 1
- APHFXDBDLKPMTA-UHFFFAOYSA-N 2-(3-decanoyl-4,5,7-trihydroxynaphthalen-2-yl)acetic acid Chemical compound CCCCCCCCCC(=O)c1c(CC(O)=O)cc2cc(O)cc(O)c2c1O APHFXDBDLKPMTA-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 description 1
- 101000874387 Astacus leptodactylus Sarcoplasmic calcium-binding protein 1 Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 description 1
- 101710177963 Baculoviral IAP repeat-containing protein 7 Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102100033680 Bombesin receptor-activated protein C6orf89 Human genes 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- ZUHQCDZJPTXVCU-UHFFFAOYSA-N C1#CCCC2=CC=CC=C2C2=CC=CC=C21 Chemical compound C1#CCCC2=CC=CC=C2C2=CC=CC=C21 ZUHQCDZJPTXVCU-UHFFFAOYSA-N 0.000 description 1
- 101150104494 CAV1 gene Proteins 0.000 description 1
- 102000053028 CD36 Antigens Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101100455063 Caenorhabditis elegans lmp-1 gene Proteins 0.000 description 1
- 101100355609 Caenorhabditis elegans rae-1 gene Proteins 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000037088 Chromosome Breakage Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100038281 Cytospin-A Human genes 0.000 description 1
- 102100027816 Cytotoxic and regulatory T-cell molecule Human genes 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 102100040606 Dermatan-sulfate epimerase Human genes 0.000 description 1
- 101100216227 Dictyostelium discoideum anapc3 gene Proteins 0.000 description 1
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 1
- 108010055196 EphA2 Receptor Proteins 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102000003817 Fos-related antigen 1 Human genes 0.000 description 1
- 108090000123 Fos-related antigen 1 Proteins 0.000 description 1
- 102100039717 G antigen 1 Human genes 0.000 description 1
- 108091072337 GAGE family Proteins 0.000 description 1
- 102000040452 GAGE family Human genes 0.000 description 1
- 102100024405 GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Human genes 0.000 description 1
- 102100030525 Gap junction alpha-4 protein Human genes 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 1
- 102100034153 Golgin subfamily A member 6B Human genes 0.000 description 1
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 1
- 102100031624 Heat shock protein 105 kDa Human genes 0.000 description 1
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 description 1
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000984746 Homo sapiens BRCA1-associated protein Proteins 0.000 description 1
- 101000944524 Homo sapiens Bombesin receptor-activated protein C6orf89 Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000884816 Homo sapiens Cytospin-A Proteins 0.000 description 1
- 101000816698 Homo sapiens Dermatan-sulfate epimerase Proteins 0.000 description 1
- 101001024566 Homo sapiens Ecto-ADP-ribosyltransferase 4 Proteins 0.000 description 1
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 description 1
- 101100449143 Homo sapiens GOLGA6B gene Proteins 0.000 description 1
- 101000981252 Homo sapiens GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 1
- 101000866478 Homo sapiens Heat shock protein 105 kDa Proteins 0.000 description 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 1
- 101001001418 Homo sapiens Inhibitor of growth protein 4 Proteins 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101001134216 Homo sapiens Macrophage scavenger receptor types I and II Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101000801664 Homo sapiens Nucleoprotein TPR Proteins 0.000 description 1
- 101100029612 Homo sapiens PHF20 gene Proteins 0.000 description 1
- 101000662592 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 description 1
- 101000872170 Homo sapiens Polycomb complex protein BMI-1 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101000583459 Homo sapiens Progesterone-induced-blocking factor 1 Proteins 0.000 description 1
- 101001069749 Homo sapiens Prospero homeobox protein 1 Proteins 0.000 description 1
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 1
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 description 1
- 101000831286 Homo sapiens Protein timeless homolog Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001062222 Homo sapiens Receptor-binding cancer antigen expressed on SiSo cells Proteins 0.000 description 1
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 description 1
- 101000727472 Homo sapiens Reticulon-4 Proteins 0.000 description 1
- 101000752245 Homo sapiens Rho guanine nucleotide exchange factor 5 Proteins 0.000 description 1
- 101000633778 Homo sapiens SLAM family member 5 Proteins 0.000 description 1
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
- 101000664703 Homo sapiens Transcription factor SOX-10 Proteins 0.000 description 1
- 101000825086 Homo sapiens Transcription factor SOX-11 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000679857 Homo sapiens Tumor necrosis factor receptor superfamily member 3 Proteins 0.000 description 1
- 101000836268 Homo sapiens U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 1
- 101000621309 Homo sapiens Wilms tumor protein Proteins 0.000 description 1
- 108010043496 Immunoglobulin Idiotypes Proteins 0.000 description 1
- 102100035677 Inhibitor of growth protein 4 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 1
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108020003285 Isocitrate lyase Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 102100034184 Macrophage scavenger receptor types I and II Human genes 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 108010092801 Midkine Proteins 0.000 description 1
- 102000016776 Midkine Human genes 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 101710141230 Natural killer cell receptor 2B4 Proteins 0.000 description 1
- 102000008730 Nestin Human genes 0.000 description 1
- 108010088225 Nestin Proteins 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 102100033615 Nucleoprotein TPR Human genes 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 102100036878 PHD finger protein 20 Human genes 0.000 description 1
- 101150038998 PLAUR gene Proteins 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 102100034640 PWWP domain-containing DNA repair factor 3A Human genes 0.000 description 1
- 108050007154 PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 102100037477 Poly [ADP-ribose] polymerase tankyrase-2 Human genes 0.000 description 1
- 102100033566 Polycomb complex protein BMI-1 Human genes 0.000 description 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 description 1
- 102100031015 Progesterone-induced-blocking factor 1 Human genes 0.000 description 1
- 102100033880 Prospero homeobox protein 1 Human genes 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100037686 Protein SSX2 Human genes 0.000 description 1
- 102100022491 RNA-binding protein NOB1 Human genes 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 102100029165 Receptor-binding cancer antigen expressed on SiSo cells Human genes 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100029831 Reticulon-4 Human genes 0.000 description 1
- 102100029216 SLAM family member 5 Human genes 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 101710114141 T-lymphocyte surface antigen Ly-9 Proteins 0.000 description 1
- 101150006914 TRP1 gene Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102100038808 Transcription factor SOX-10 Human genes 0.000 description 1
- 102100022415 Transcription factor SOX-11 Human genes 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100022156 Tumor necrosis factor receptor superfamily member 3 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 1
- 101150042088 UL16 gene Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 description 1
- 101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 description 1
- 101100060882 Yersinia pestis pla gene Proteins 0.000 description 1
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 108010072917 class-I restricted T cell-associated molecule Proteins 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 108010015408 connexin 37 Proteins 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 108010048032 cyclophilin B Proteins 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108010006620 fodrin Proteins 0.000 description 1
- 102000054078 gamma Catenin Human genes 0.000 description 1
- 108010084448 gamma Catenin Proteins 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 108010066416 multidrug resistance-associated protein 3 Proteins 0.000 description 1
- 210000005055 nestin Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 108010044156 peptidyl-prolyl cis-trans isomerase b Proteins 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 108010078070 scavenger receptors Proteins 0.000 description 1
- 102000014452 scavenger receptors Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002483 superagonistic effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021168585A JP7497054B2 (ja) | 2016-07-13 | 2021-10-14 | 抗原提示細胞模倣足場およびそれを作製および使用するための方法 |
| JP2024047889A JP7758384B2 (ja) | 2016-07-13 | 2024-03-25 | 抗原提示細胞模倣足場およびそれを作製および使用するための方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662361891P | 2016-07-13 | 2016-07-13 | |
| US62/361,891 | 2016-07-13 | ||
| PCT/US2017/041912 WO2018013797A1 (en) | 2016-07-13 | 2017-07-13 | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021168585A Division JP7497054B2 (ja) | 2016-07-13 | 2021-10-14 | 抗原提示細胞模倣足場およびそれを作製および使用するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019522486A JP2019522486A (ja) | 2019-08-15 |
| JP2019522486A5 true JP2019522486A5 (https=) | 2020-08-20 |
Family
ID=60952765
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019501623A Withdrawn JP2019522486A (ja) | 2016-07-13 | 2017-07-13 | 抗原提示細胞模倣足場およびそれを作製および使用するための方法 |
| JP2021168585A Active JP7497054B2 (ja) | 2016-07-13 | 2021-10-14 | 抗原提示細胞模倣足場およびそれを作製および使用するための方法 |
| JP2024047889A Active JP7758384B2 (ja) | 2016-07-13 | 2024-03-25 | 抗原提示細胞模倣足場およびそれを作製および使用するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021168585A Active JP7497054B2 (ja) | 2016-07-13 | 2021-10-14 | 抗原提示細胞模倣足場およびそれを作製および使用するための方法 |
| JP2024047889A Active JP7758384B2 (ja) | 2016-07-13 | 2024-03-25 | 抗原提示細胞模倣足場およびそれを作製および使用するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11555177B2 (https=) |
| EP (2) | EP3484448B1 (https=) |
| JP (3) | JP2019522486A (https=) |
| CN (4) | CN109789092A (https=) |
| AU (2) | AU2017295704B2 (https=) |
| CA (1) | CA3030427A1 (https=) |
| DK (1) | DK3484448T3 (https=) |
| ES (1) | ES3032115T3 (https=) |
| FI (1) | FI3484448T3 (https=) |
| MA (1) | MA45738A (https=) |
| WO (1) | WO2018013797A1 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007070660A2 (en) | 2005-12-13 | 2007-06-21 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
| CN107648668B (zh) | 2010-10-06 | 2021-06-18 | 哈佛学院董事会 | 用于基于材料的细胞疗法的可注射的成孔水凝胶 |
| US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
| DK2838515T3 (da) | 2012-04-16 | 2020-02-24 | Harvard College | Mesoporøse siliciumdioxidsammensætninger til modulering af immunresponser |
| EP4282419A1 (en) | 2012-12-20 | 2023-11-29 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| EP3137105A4 (en) | 2014-04-30 | 2017-12-27 | President and Fellows of Harvard College | Combination vaccine devices and methods of killing cancer cells |
| US11786457B2 (en) | 2015-01-30 | 2023-10-17 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| WO2016164705A1 (en) | 2015-04-10 | 2016-10-13 | Omar Abdel-Rahman Ali | Immune cell trapping devices and methods for making and using the same |
| US11752238B2 (en) | 2016-02-06 | 2023-09-12 | President And Fellows Of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
| MA44252A (fr) * | 2016-02-16 | 2018-12-26 | Harvard College | Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| JP6987080B2 (ja) | 2016-05-05 | 2021-12-22 | サウスウェスト リサーチ インスティテュート | 細胞増殖のための三次元バイオリアクター及び関連用途 |
| CN109789092A (zh) * | 2016-07-13 | 2019-05-21 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
| IL264557B2 (en) | 2016-08-02 | 2024-01-01 | Harvard College | Biological agents for regulating immune responses |
| US11649288B2 (en) | 2017-02-07 | 2023-05-16 | Seattle Children's Hospital | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents |
| WO2018160622A1 (en) | 2017-02-28 | 2018-09-07 | Endocyte, Inc. | Compositions and methods for car t cell therapy |
| US11311576B2 (en) | 2018-01-22 | 2022-04-26 | Seattle Children's Hospital | Methods of use for CAR T cells |
| GB201801902D0 (en) * | 2018-02-06 | 2018-03-21 | Stichting Katholieke Univ | Immunomodulatory nanofilaments |
| US12312416B2 (en) | 2018-02-06 | 2025-05-27 | Seattle Children's Hospital | Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors |
| EP3755347B1 (en) * | 2018-02-21 | 2025-06-25 | Board of Regents, The University of Texas System | Universal antigen presenting cells and uses thereof |
| US12473336B2 (en) | 2018-02-21 | 2025-11-18 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses thereof |
| AU2019225174B2 (en) | 2018-02-23 | 2025-11-20 | Endocyte, Inc. | Sequencing method for CAR T cell therapy |
| MA52114A (fr) | 2018-02-28 | 2021-01-06 | Juno Therapeutics Inc | Procédés de détection de particules présentes dans une composition cellulaire |
| US11149244B2 (en) | 2018-04-04 | 2021-10-19 | Southwest Research Institute | Three-dimensional bioreactor for T-cell activation and expansion for immunotherapy |
| KR20210074274A (ko) * | 2018-08-06 | 2021-06-21 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 합텐 표지된 세포로의 키메라 항원 수용체 t 세포의 자극을 위한 방법 및 조성물 |
| WO2020061129A1 (en) | 2018-09-19 | 2020-03-26 | President And Fellows Of Harvard College | Compositions and methods for labeling and modulation of cells in vitro and in vivo |
| JP7376576B2 (ja) | 2018-09-24 | 2023-11-08 | サウスウェスト リサーチ インスティテュート | 三次元バイオリアクター |
| CA3122843A1 (en) * | 2018-12-12 | 2020-06-18 | The Brigham And Women's Hospital, Inc. | Compositions and methods for immunosuppression |
| US20220152150A1 (en) * | 2019-02-25 | 2022-05-19 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| WO2021061837A1 (en) | 2019-09-23 | 2021-04-01 | President And Fellows Of Harvard College | Biomaterial-based antigen free vaccine and the use thereof |
| WO2021155297A1 (en) * | 2020-01-29 | 2021-08-05 | President And Fellows Of Harvard College | Methods for labeling and targeting cells |
| CN115210252A (zh) | 2020-02-04 | 2022-10-18 | 西雅图儿童医院（Dba西雅图儿童研究所） | 抗二硝基苯酚的嵌合抗原受体 |
| CN115397440A (zh) * | 2020-02-04 | 2022-11-25 | 西雅图儿童医院（Dba西雅图儿童研究所） | 用半抗原标记细胞刺激嵌合抗原受体t细胞的方法和组合物 |
| US11492580B2 (en) | 2020-05-12 | 2022-11-08 | Southwest Research Institute | Method using a three-dimensional bioprocessor |
| MX2023002107A (es) | 2020-08-21 | 2023-03-15 | Novartis Ag | Composiciones y metodos para la generacion in vivo de celulas que expresan car. |
| WO2022072393A1 (en) * | 2020-09-29 | 2022-04-07 | University Of Washington | Use of a double-stranded dna cytosine deaminase for mapping dna-protein interactions |
| CN113413462B (zh) * | 2021-06-23 | 2022-07-12 | 中国科学院上海硅酸盐研究所 | 模拟自然杀伤细胞高效治疗胞内菌用纳米材料及其制备方法和应用 |
| AU2022378579A1 (en) | 2021-10-28 | 2024-05-02 | Lyell Immunopharma, Inc. | Methods of generating cells |
| IL312204A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for culturing cells expressing ror1-binding protein |
| IL312201A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for culturing cells expressing c-jun |
| AU2022377625B2 (en) | 2021-10-28 | 2025-01-02 | Southwest Research Institute | Devices for cell separation |
| WO2023147185A1 (en) * | 2022-01-31 | 2023-08-03 | President And Fellows Of Harvard College | Methods for making and using antigen-presenting cell-mimetic scaffolds to enhance t-cell therapies |
| WO2023228182A1 (en) * | 2022-05-23 | 2023-11-30 | Pluri Biotech Ltd. | System and methods for immune cells expansion and activation in large scale |
| CN115154618A (zh) * | 2022-07-19 | 2022-10-11 | 杭州准星医学科技有限公司 | 一种针对癌性腹水的介孔二氧化硅缓释制剂及其制备方法 |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| WO2026006604A1 (en) | 2024-06-26 | 2026-01-02 | Lyell Immunopharma, Inc. | Feeder cell replacement |
Family Cites Families (312)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5102872A (en) * | 1985-09-20 | 1992-04-07 | Cetus Corporation | Controlled-release formulations of interleukin-2 |
| US5496924A (en) | 1985-11-27 | 1996-03-05 | Hoechst Aktiengesellschaft | Fusion protein comprising an interleukin-2 fragment ballast portion |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| GB9206504D0 (en) | 1992-03-25 | 1992-05-06 | Jevco Ltd | Heteromorphic sponges as wound implants |
| DE69431404T2 (de) | 1993-10-22 | 2003-04-30 | Genentech Inc., San Francisco | Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe |
| US6913767B1 (en) | 1993-10-25 | 2005-07-05 | Genentech, Inc. | Compositions for microencapsulation of antigens for use as vaccines |
| EP0741580A4 (en) | 1993-12-14 | 2001-07-11 | Univ Johns Hopkins Med | Controlled release of pharmaceutically active substances for immunotherapy |
| US5538733A (en) | 1994-07-07 | 1996-07-23 | Willmar Poultry Company, Inc. | Method of priming an immune response in a one-day old animal |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| EP1167379A3 (en) | 1994-07-15 | 2004-09-08 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
| US6329499B1 (en) | 1994-11-18 | 2001-12-11 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein |
| US6251396B1 (en) | 1994-11-18 | 2001-06-26 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein |
| US5674677A (en) | 1994-12-21 | 1997-10-07 | The Center For Innovative Technology | Immunoassay technique using histidine tags, metals, and chelating agents |
| US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
| US5658588A (en) * | 1995-03-31 | 1997-08-19 | University Of Cincinnati | Fibrinogen-coated liposomes |
| GB9514285D0 (en) | 1995-07-13 | 1995-09-13 | Univ Nottingham | Polymeric lamellar substrate particles for drug delivery |
| US5951976A (en) | 1996-03-28 | 1999-09-14 | Whitenead Institute For Biomedical Research | Opsonin-enhanced cells, and methods of modulating an immune response to an antigen |
| IL118376A0 (en) | 1996-05-22 | 1996-09-12 | Univ Ben Gurion | Polysaccharide sponges for cell culture and transplantation |
| US5885829A (en) | 1996-05-28 | 1999-03-23 | The Regents Of The University Of Michigan | Engineering oral tissues |
| US6124128A (en) | 1996-08-16 | 2000-09-26 | The Regents Of The University Of California | Long wavelength engineered fluorescent proteins |
| ES2317657T3 (es) | 1996-09-19 | 2009-04-16 | The Regents Of The University Of Michigan | Polimeros que contienen polisacaridos tales como alginatos o alginatos modificados. |
| US5863551A (en) | 1996-10-16 | 1999-01-26 | Organogel Canada Ltee | Implantable polymer hydrogel for therapeutic uses |
| GB2318577B (en) | 1996-10-28 | 2000-02-02 | Johnson & Johnson Medical | Solvent dried polysaccharide sponges |
| GB2323282B (en) | 1997-03-17 | 2001-03-07 | Bristol Myers Squibb Co | Improvements relating to hygiene and medical products |
| ATE249491T1 (de) | 1997-03-31 | 2003-09-15 | Univ Michigan | Offenporige bioabbaubare matrize |
| ATE412383T1 (de) | 1997-05-30 | 2008-11-15 | Osteobiologics Inc | Faserverstärkte,poröse,biologisch abbaubare implantatvorrichtung |
| JP3990736B2 (ja) | 1997-08-21 | 2007-10-17 | タカラバイオ株式会社 | 制がん剤 |
| HUP0003513A3 (en) | 1997-09-11 | 2004-05-28 | Chugai Pharmaceutical Co Ltd | Monoclonal antibody inducing apoptosis |
| BR9907968B1 (pt) | 1998-02-23 | 2009-12-01 | composição de polìmeros com memória de formato biodegradáveis e artigos compreendendo a mesma. | |
| CA2322435A1 (en) | 1998-03-02 | 1999-09-10 | Applied Vaccine Technologies Corp. | Methods and devices for modulating the immune response |
| AU760549B2 (en) | 1998-04-03 | 2003-05-15 | University Of Iowa Research Foundation, The | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
| WO1999052356A1 (en) | 1998-04-09 | 1999-10-21 | Charlotte-Mecklenberg Hospital Authority | Creation of three-dimensional tissues |
| US7427602B1 (en) | 1998-05-13 | 2008-09-23 | The Regents Of The University Of Michigan | Sustained DNA delivery from structural matrices |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US6087452A (en) | 1998-06-02 | 2000-07-11 | University Of Utah | Metal-chelating surfacant |
| US7244714B1 (en) | 1998-06-12 | 2007-07-17 | Aradigm Corporation | Methods of delivering aerosolized polynucleotides to the respiratory tract |
| FR2780730B1 (fr) | 1998-07-01 | 2000-10-13 | Corneal Ind | Compositions biphasiques injectables, notamment utiles en chirurgies reparatrice et esthetique |
| AU766826B2 (en) | 1998-07-30 | 2003-10-23 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Thymosin beta4 promotes wound repair |
| US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| WO2000021572A2 (en) | 1998-10-09 | 2000-04-20 | The University Of Michigan | Hydrogels and water soluble polymeric carriers for drug delivery |
| KR100629028B1 (ko) | 1998-10-16 | 2006-09-26 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 애쥬번트 시스템 및 백신 |
| GB9823897D0 (en) | 1998-11-02 | 1998-12-30 | Imp College Innovations Ltd | Immunotherapeutic methods and molecules |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6974698B1 (en) | 1999-01-15 | 2005-12-13 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for delivering biologically active molecules into cells |
| EP1156781B1 (en) | 1999-02-26 | 2005-06-08 | Chiron Corporation | Microemulsions with adsorbed macromolecules and microparticles |
| US6767928B1 (en) | 1999-03-19 | 2004-07-27 | The Regents Of The University Of Michigan | Mineralization and biological modification of biomaterial surfaces |
| US6541022B1 (en) | 1999-03-19 | 2003-04-01 | The Regents Of The University Of Michigan | Mineral and cellular patterning on biomaterial surfaces |
| JP5031144B2 (ja) | 1999-03-25 | 2012-09-19 | メタボリックス，インコーポレイテッド | ポリヒドロキシアルカノエートポリマーの医療デバイスおよび医療適用 |
| AU776009B2 (en) | 1999-04-09 | 2004-08-26 | Regents Of The University Of Michigan, The | Preparing porous hydrogel products |
| US6306424B1 (en) | 1999-06-30 | 2001-10-23 | Ethicon, Inc. | Foam composite for the repair or regeneration of tissue |
| AU782297B2 (en) | 1999-06-30 | 2005-07-14 | Ethicon Inc. | Porous tissue scaffoldings for the repair or regeneration of tissue |
| US8084258B2 (en) | 1999-07-12 | 2011-12-27 | University Of Basel | Manipulation of tissue of organ type using the notch pathway |
| AU6526100A (en) | 1999-08-06 | 2001-03-05 | Board Of Regents, The University Of Texas System | Drug releasing biodegradable fiber implant |
| US7015205B1 (en) | 1999-10-18 | 2006-03-21 | St. Vincent's Hospital And Medical Center Of New York | Melanoma vaccine and methods of making and using same |
| WO2001035932A2 (en) | 1999-11-18 | 2001-05-25 | The Regents Of The University Of Michigan | Sustained drug delivery from structural matrices |
| US6682754B2 (en) | 1999-11-24 | 2004-01-27 | Willmar Poultry Company, Inc. | Ovo delivery of an immunogen containing implant |
| US6790840B1 (en) | 1999-11-26 | 2004-09-14 | The Regents Of The University Of Michigan | Reversibly cross-linked hydrogels |
| US20020061587A1 (en) | 2000-07-31 | 2002-05-23 | Piero Anversa | Methods and compositions for the repair and/or regeneration of damaged myocardium |
| EP1311657A2 (en) | 2000-08-21 | 2003-05-21 | Rice University | Tissue engineering scaffolds promoting matrix protein production |
| AU8843701A (en) | 2000-09-09 | 2002-03-22 | Univ New York State Res Found | Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof |
| US6748954B2 (en) | 2000-10-27 | 2004-06-15 | The Regents Of The University Of Michigan | Drug release from polymer matrices through mechanical stimulation |
| WO2002040071A1 (en) | 2000-11-14 | 2002-05-23 | Osteogenesis Co., Ltd. | Compositions for forming bone or periodontium and injections for forming bone or periodontium |
| WO2002041913A1 (en) | 2000-11-27 | 2002-05-30 | Jens Christian Jensenius | Collectins as adjuvants |
| US8554940B2 (en) | 2001-01-19 | 2013-10-08 | Single Touch Interactive, Inc. | System and method for routing media |
| JP2004520043A (ja) | 2001-01-24 | 2004-07-08 | シェーリング コーポレイション | 免疫応答のアジュバントとしてのケモカイン |
| US7029697B2 (en) | 2001-02-14 | 2006-04-18 | Northwestern University | Controlled surface-associated delivery of genes and oligonucleotides |
| JP4215512B2 (ja) | 2001-02-26 | 2009-01-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 非オリゴマー化タンデム蛍光性タンパク質 |
| JP2002263981A (ja) | 2001-03-14 | 2002-09-17 | Murata Mach Ltd | 板材吸着持ち上げ装置の吸着制御装置 |
| DK2336167T3 (da) | 2001-03-14 | 2019-09-02 | Dako Denmark As | MHC-molekylkonstrukter og deres anvendelse til diagnose og terapi |
| US20020131953A1 (en) | 2001-03-14 | 2002-09-19 | Ut Southwestern Medical Center | In situ langerhans cell vaccine |
| US6656488B2 (en) | 2001-04-11 | 2003-12-02 | Ethicon Endo-Surgery, Inc. | Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering |
| US20030082806A1 (en) | 2001-04-27 | 2003-05-01 | Xcyte Therapies, Inc. | Maturation of antigen-presenting cells using activated T cells |
| US6958158B2 (en) | 2001-05-11 | 2005-10-25 | Ortho-Mcneil Pharmaceutical, Inc. | Immune modulation device for use in animals |
| US20030118630A1 (en) | 2001-12-07 | 2003-06-26 | Anthony Cerami | Immune modulation device for use in animals |
| EP1407261A4 (en) | 2001-06-13 | 2006-11-22 | Massachusetts Inst Technology | BIOREACTORS FOR IN VIVO REACTIONS |
| US7297343B2 (en) | 2001-07-31 | 2007-11-20 | Biosurface Engineering Technologies, Inc. | Bioactive medical films |
| WO2003020884A2 (en) | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
| CA2412012C (en) | 2001-11-20 | 2011-08-02 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage |
| EP1469865A4 (en) | 2001-12-31 | 2010-04-14 | Crosslink D Inc | HEMOSTATIC COMPOSITIONS AND METHODS FOR CONTROLLING HEMORRHAGIA |
| US7575759B2 (en) | 2002-01-02 | 2009-08-18 | The Regents Of The University Of Michigan | Tissue engineering scaffolds |
| WO2003070291A1 (en) | 2002-02-19 | 2003-08-28 | National Institute Of Advanced Industrial Science And Technology | Implant containing cells having growhfactor gene transferred thereinto |
| US20070026518A1 (en) | 2005-03-29 | 2007-02-01 | The Regents Of The University Of California | Controlling stem cell destiny with tunable matrices |
| US20080233181A1 (en) | 2002-04-12 | 2008-09-25 | Nagy Jon O | Nanoparticle adjuvants for sub-unit vaccines |
| US6811777B2 (en) | 2002-04-13 | 2004-11-02 | Allan Mishra | Compositions and minimally invasive methods for treating incomplete connective tissue repair |
| KR101092043B1 (ko) | 2002-04-22 | 2011-12-12 | 바이오니취 라이프 사이언시즈 인코포레이티드 | 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도 |
| WO2003089506A1 (en) | 2002-04-22 | 2003-10-30 | Purdue Research Foundation | Hydrogels having enhanced elasticity and mechanical strength properties |
| AU2003249606A1 (en) | 2002-05-13 | 2003-12-02 | Massachusetts Institute Of Technology | Angiogenesis and cardiac tissue engineering with peptide hydrogels and related compositions and methods of use thereof |
| AUPS312602A0 (en) | 2002-06-21 | 2002-07-18 | James Cook University | Organ arrest, protection, preservation and recovery |
| US7332160B2 (en) | 2002-07-12 | 2008-02-19 | Boston Scientific Scimed, Inc. | Medical device and method for tissue removal and repair |
| GB2392158B (en) | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| DE60327786D1 (de) | 2002-09-12 | 2009-07-09 | Oncotherapy Science Inc | Kdr-peptide und diese enthaltende impfstoffe |
| US20040136968A1 (en) | 2002-09-27 | 2004-07-15 | Verigen Ag | Autologous cells on a support matrix for tissue repair |
| US20040063206A1 (en) | 2002-09-30 | 2004-04-01 | Rowley Jon A. | Programmable scaffold and method for making and using the same |
| WO2004030706A2 (en) | 2002-10-01 | 2004-04-15 | Law Peter K | Bioactive implants |
| JP2004159849A (ja) | 2002-11-12 | 2004-06-10 | National Institute Of Advanced Industrial & Technology | 細胞接着性生体吸収材料、人工血管およびそれらの製造方法 |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US8940292B2 (en) | 2003-01-28 | 2015-01-27 | Wake Forest University Health Sciences | Enhancement of angiogenesis to grafts using cells engineered to produce growth factors |
| SE0301109D0 (sv) | 2003-04-14 | 2003-04-14 | Mallen Huang | Nucleotide vaccine composition |
| KR101180896B1 (ko) | 2003-05-05 | 2012-09-07 | 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 | 주사용 가교결합된 폴리머 제제 및 그의 용도 |
| EP1475434A1 (en) | 2003-05-09 | 2004-11-10 | Oncoscience AG | Method for storing tumor cells |
| US20050053667A1 (en) | 2003-07-09 | 2005-03-10 | Darrell Irvine | Programmed immune responses using a vaccination node |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| US20060264380A1 (en) | 2003-07-21 | 2006-11-23 | Mats Hellstrom | Compounds and Methods for Promoting Angiogenesis |
| EP1651259A4 (en) | 2003-07-31 | 2008-05-28 | Endacea Inc | METHOD AND COMPOSITIONS FOR PRODUCING ANTIGENIC ANSWERS |
| GB0317999D0 (en) | 2003-07-31 | 2003-09-03 | Univ Liege | Improvements in or relating to drug delivery systems |
| AU2004268013B2 (en) | 2003-08-29 | 2011-05-12 | Mayo Foundation For Medical Education And Research | Hydrogel porogens for fabricating biodegradable scaffolds |
| CA2537900A1 (en) | 2003-09-03 | 2005-04-28 | Dendritherapeutics, Inc. | Multiplex vaccines |
| GB0321615D0 (en) | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
| EP2591786B1 (en) | 2003-10-16 | 2017-04-12 | Cancure Limited | Immunomodulating compositions and uses therefor |
| US8162925B2 (en) | 2003-11-07 | 2012-04-24 | Carnegie Mellon University | Robot for minimally invasive interventions |
| CA2448995A1 (en) | 2003-11-12 | 2005-05-12 | James Keenan | Device and method for attracting diseased cells and foreign substances |
| JP2005160669A (ja) | 2003-12-02 | 2005-06-23 | Olympus Corp | 生体組織補填体の製造方法 |
| JP2005170816A (ja) | 2003-12-09 | 2005-06-30 | Naoki Ishiguro | 軟骨修復用材料、およびその製造方法 |
| JP2005168760A (ja) | 2003-12-10 | 2005-06-30 | Gunze Ltd | 再生医療用支持体、血管再生用支持体、神経再生用支持体及び治療方法 |
| CA2548992A1 (en) | 2003-12-11 | 2005-08-11 | Vaxdesign Corporation | Immunotherapy compositions, method of making and method of use thereof |
| US11395865B2 (en) | 2004-02-09 | 2022-07-26 | DePuy Synthes Products, Inc. | Scaffolds with viable tissue |
| US7192693B2 (en) | 2004-02-24 | 2007-03-20 | University Of Washington | Methods for photopatterning hydrogels |
| WO2005089777A1 (en) | 2004-03-15 | 2005-09-29 | Karaolis David K R | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| JP5795699B2 (ja) | 2004-04-28 | 2015-10-14 | サノフィ パスツール ヴァックスデザイン コーポレーション | 人工免疫システム：作製および使用方法 |
| US20080113929A1 (en) | 2004-06-08 | 2008-05-15 | Coley Pharmaceutical Gmbh | Abasic Oligonucleotide as Carrier Platform for Antigen and Immunostimulatory Agonist and Antagonist |
| US8080245B2 (en) | 2004-08-04 | 2011-12-20 | University Of Massachusetts | Anti-pathogen immunoadhesins |
| EP1784493A2 (en) | 2004-09-01 | 2007-05-16 | The Government of the United States of America as Represented by The Department of Health and Human Services | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
| EP1799232B1 (en) | 2004-10-12 | 2015-10-07 | FMC Biopolymer AS | Self-gelling alginate systems and uses thereof |
| US7235592B2 (en) | 2004-10-12 | 2007-06-26 | Zimmer Gmbh | PVA hydrogel |
| US7999161B2 (en) | 2005-01-22 | 2011-08-16 | Alexander Oraevsky | Laser-activated nanothermolysis of cells |
| US7569850B2 (en) | 2005-01-24 | 2009-08-04 | Lawrence Livermore National Security, Llc | Lipid bilayers on nano-templates |
| CA2602905A1 (en) | 2005-03-23 | 2006-09-28 | Mayo Foundation For Medical Education And Research | Photocrosslinkable oligo(poly (ethylene glycol) fumarate) hydrogels for cell and drug delivery |
| EP1712238A1 (en) | 2005-04-11 | 2006-10-18 | Institut Gustave Roussy | Anthracyclin induced immunogenic dead or dying cells composition |
| US20070003595A1 (en) | 2005-04-19 | 2007-01-04 | Shaopeng Wang | Three dimensional micro-environments and methods of making and using same |
| US8828433B2 (en) | 2005-04-19 | 2014-09-09 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
| CN103285392A (zh) | 2005-04-26 | 2013-09-11 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和其用途 |
| WO2006119619A1 (en) | 2005-05-06 | 2006-11-16 | Replicor Inc. | Oligonucleotides inhibiting cell proliferation |
| ITPI20050071A1 (it) | 2005-06-20 | 2006-12-21 | Giuseppe Calvosa | Composizione biocompatibile per la sostituzione/rigenerazione di tessuti |
| US7645742B2 (en) | 2005-06-22 | 2010-01-12 | Advocare International, L.P. | Composition for enhancing cellular energy |
| CN1302050C (zh) | 2005-07-07 | 2007-02-28 | 复旦大学 | 一种互穿网络聚合物超多孔水凝胶及其制备方法和应用 |
| US20090017096A1 (en) | 2005-08-15 | 2009-01-15 | Anthony Lowman | Porous non-biodegradable hydrogel admixed with a chemoattractant for tissue replacement |
| US20070060658A1 (en) | 2005-08-31 | 2007-03-15 | Diaz David D | Stabilization of organogels and hydrogels by azide-alkyne [3+2] cycloaddition |
| BRPI0503817A (pt) | 2005-09-12 | 2007-05-15 | Cristalia Prod Quimicos Farm | complexo imunogênico formado por antìgenos vacinais encapsulados por sìlica mesoporosa nanoestruturada |
| AU2006291429B2 (en) | 2005-09-15 | 2013-04-04 | Biontech Delivery Technologies Gmbh | Improvements in or relating to amphoteric liposomes |
| KR101536239B1 (ko) | 2005-09-23 | 2015-07-13 | 셀레릭스, 에스.엘. | 면역조절활성을 갖는 세포 개체군, 분리 방법 및 용도 |
| US20070081972A1 (en) | 2005-09-30 | 2007-04-12 | The University Of Iowa Research Foundation | Polymer-based delivery system for immunotherapy of cancer |
| KR20080065656A (ko) | 2005-10-12 | 2008-07-14 | 캔써 리서치 테크놀로지 리미티드 | 면역질환을 치료하기 위한 방법 및 조성물 |
| US8029575B2 (en) | 2005-10-25 | 2011-10-04 | Globus Medical, Inc. | Porous and nonporous materials for tissue grafting and repair |
| US20070116680A1 (en) | 2005-11-18 | 2007-05-24 | Rensselaer Polytechnic Institute | Stem cells within gel microenvironments |
| ES2405552T3 (es) | 2005-11-29 | 2013-05-31 | Actogenix N.V. | Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos |
| KR100687281B1 (ko) | 2005-11-30 | 2007-02-27 | 한국과학기술연구원 | 생리 활성 물질이 결합된 조직 재생용 주입형 온도 감응성플루로닉 유도체 하이드로겔 및 이의 제조 방법 |
| PL1957044T3 (pl) | 2005-12-01 | 2013-11-29 | Pronai Therapeutics Inc | Amfoteryczny preparat liposomowy |
| AU2015264807A1 (en) | 2005-12-13 | 2015-12-17 | President And Fellows Of Harvard College | Scaffolds for Cell Transplantation |
| AU2014200405B2 (en) | 2005-12-13 | 2015-09-03 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
| WO2007070660A2 (en) | 2005-12-13 | 2007-06-21 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
| CN101330934B (zh) | 2005-12-14 | 2013-03-20 | Scil技术有限公司 | 一种用于骨再生的可模压的生物材料及其制备方法和用途 |
| EP1806395A1 (en) | 2006-01-06 | 2007-07-11 | Stichting Sanquin Bloedvoorziening | Maturation of dendritic cells |
| US7615556B2 (en) | 2006-01-27 | 2009-11-10 | Bristol-Myers Squibb Company | Piperazinyl derivatives as modulators of chemokine receptor activity |
| US20070178159A1 (en) | 2006-01-30 | 2007-08-02 | Alza Corporation | In-Situ Forming Porous Scaffold |
| WO2007089870A2 (en) | 2006-01-31 | 2007-08-09 | Medivas, Llc | Vaccine delivery compositions and methods of use |
| US20100015709A1 (en) | 2006-02-10 | 2010-01-21 | Trustees Of The University Of Pennsylvania | Regulating Stem Cell Differentiation By Controlling 2D and 3D Matrix Elasticity |
| US20090041825A1 (en) | 2006-02-10 | 2009-02-12 | Kotov Nicholas A | Cell culture well-plates having inverted colloidal crystal scaffolds |
| US20070190646A1 (en) | 2006-02-10 | 2007-08-16 | The Trustees Of The University Of Pennsylvania | Regulating stem cell differentiation by controlling matrix elasticity |
| CN101405037A (zh) | 2006-02-27 | 2009-04-08 | 新加坡科技研究局 | 可固化骨粘固剂 |
| US9456860B2 (en) | 2006-03-14 | 2016-10-04 | Kci Licensing, Inc. | Bioresorbable foaming tissue dressing |
| GB0605521D0 (en) | 2006-03-18 | 2006-04-26 | Isis Innovation | Adjuvant |
| US20090297579A1 (en) | 2006-06-01 | 2009-12-03 | Massachusetts Institute Of Technology | Control of Cells and Cell Multipotentiality in Three Dimensional Matrices |
| WO2007146319A2 (en) | 2006-06-13 | 2007-12-21 | Symphony Medical, Inc. | Methods and apparatus for using polymer-based beads and hydrogels for cardiac applications |
| US20070298067A1 (en) | 2006-06-22 | 2007-12-27 | Boston Scientific Scimed, Inc. | Control release drug coating for medical devices |
| CA2690973A1 (en) | 2006-06-23 | 2007-12-27 | Paul M. Simon | Targeted immune conjugates |
| WO2008008266A2 (en) | 2006-07-07 | 2008-01-17 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Biohybrid elastomeric scaffolds and methods of use thereof |
| US7993918B2 (en) | 2006-08-04 | 2011-08-09 | Anthrogenesis Corporation | Tumor suppression using placental stem cells |
| KR100802139B1 (ko) | 2006-08-08 | 2008-02-11 | 한국생명공학연구원 | 자성 나노입자를 함유하는 골드 나노케이지 |
| KR100818708B1 (ko) | 2006-08-18 | 2008-04-01 | 주식회사 하이닉스반도체 | 표면 세정을 포함하는 반도체소자 제조방법 |
| JP2010502224A (ja) | 2006-09-08 | 2010-01-28 | アボット・ラボラトリーズ | インターロイキン１３結合タンパク質 |
| ITMI20061726A1 (it) | 2006-09-11 | 2008-03-12 | Fidia Farmaceutici | Derivati crosslinkati a base di acido ialuronico reticolato via click chemistry |
| WO2008036393A1 (en) | 2006-09-21 | 2008-03-27 | Purdue Research Foundation | Collagen preparation and method of isolation |
| AU2007306936B2 (en) | 2006-10-12 | 2014-02-06 | The University Of Queensland | Compositions and methods for modulating immune responses |
| TWI362925B (en) | 2006-11-09 | 2012-05-01 | Kci Licensing Inc | Method for preparing a bioresorbable dressing comprising bioresorbable microparticles and method for preparing a bioresorbable dressing comprising bioresorbable microspheres |
| US8709464B2 (en) | 2007-01-10 | 2014-04-29 | The Regents Of The University Of Michigan | Porous objects having immobilized encapsulated biomolecules |
| CN101678090B (zh) | 2007-03-07 | 2012-04-11 | 乌第有限合伙公司 | 用于预防和治疗自身免疫病的组合物和方法 |
| WO2008114149A2 (en) | 2007-03-21 | 2008-09-25 | Id Biomedical Corporation Of Quebec | Chimeric antigens |
| US8501905B2 (en) | 2007-03-22 | 2013-08-06 | The Regents Of The University Of California | Synthetic cell platforms and methods of use thereof |
| EP1975230A1 (en) | 2007-03-30 | 2008-10-01 | Capsulution Nanoscience AG | Method for forming glucose sensing micro-particles, use of micro-particles, and kit |
| WO2008131074A1 (en) | 2007-04-19 | 2008-10-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders |
| BRPI0812205A2 (pt) | 2007-06-05 | 2014-11-25 | Novartis Ag | Indução de fenótipo tolerogênico em células dendríticas maduras |
| EP2167647A2 (en) | 2007-06-13 | 2010-03-31 | La Jolla Institute For Allergy And Immunology | Regulatory t cells and methods of making and using same |
| US9770535B2 (en) | 2007-06-21 | 2017-09-26 | President And Fellows Of Harvard College | Scaffolds for cell collection or elimination |
| WO2009005769A2 (en) | 2007-06-29 | 2009-01-08 | The Trustees Of The University Of Pennsylvania | Soft gel systems in modulating stem cell development |
| RU2010107199A (ru) | 2007-07-31 | 2011-09-10 | Дзе Джонс Хопкинс Юниверсити (Us) | Конъюгат полипептид-нуклеиновая кислота для иммунопрофилактики или иммунотерапии для неопластических или инфекционных нарушений |
| GB0716264D0 (en) | 2007-08-21 | 2007-09-26 | Isis Innovation | Bilayers |
| US20090192079A1 (en) | 2007-10-09 | 2009-07-30 | Genzyme Corporation | Prolonged delivery of heparin-binding growth factors from heparin-derivatized collagen |
| JP2011500569A (ja) * | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
| EP2222341B1 (en) | 2007-11-21 | 2015-02-25 | University Of Georgia Research Foundation, Inc. | Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds |
| KR100900837B1 (ko) | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물 |
| EP2072617A1 (en) | 2007-12-12 | 2009-06-24 | Trimed Biotech GmbH | Method for producing dendritic cells |
| DE102008008522A1 (de) | 2008-02-11 | 2009-08-13 | Magforce Nanotechnologies Ag | Implantierbare Nanopartikel-enthaltende Produkte |
| WO2011063336A2 (en) | 2009-11-20 | 2011-05-26 | President And Fellows Of Harvard College | Secondary site of antigen stimulation for therapeutic vaccination |
| US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
| CN102006891B (zh) | 2008-02-13 | 2017-04-26 | 哈佛学院董事会 | 连续的细胞程序化装置 |
| US20090238853A1 (en) | 2008-03-21 | 2009-09-24 | 3D Biotek, Llc | Hybrid Biomedical Device Fabricated From Biomaterials and Coated With a Natural Extra Cellular Matrix (ECM) Coating |
| EP2711021B1 (en) | 2008-05-02 | 2016-03-09 | BliNK Therapeutics Limited | Products and methods for stimulating an immune response |
| WO2009146456A1 (en) | 2008-05-30 | 2009-12-03 | President And Fellows Of Harvard College | Controlled release of growth factors and signaling molecules for promoting angiogenesis |
| WO2009155583A1 (en) | 2008-06-19 | 2009-12-23 | The Trustees Of The University Of Pennsylvania | Biomaterials for tissue replacement |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| US8889124B2 (en) | 2008-09-25 | 2014-11-18 | The Board Of Trustees Of The Leland Stanford Junior University | Tolerogenic populations of dendritic cells |
| US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8940331B2 (en) | 2008-11-22 | 2015-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrogels, methods of making hydrogels, methods of using hydrogels, and methods of isolating, trapping, attracting, and/or killing cancer cells |
| KR101132732B1 (ko) | 2008-11-26 | 2012-04-06 | 한국과학기술연구원 | 인 시튜 조직재생용 지능형 다공성 생분해 고분자 지지체 및 이의 제조방법 |
| WO2010065135A1 (en) | 2008-12-04 | 2010-06-10 | Searete, Llc | System, devices, and methods including actively-controllable sterilizing excitation delivery implants |
| US8273373B2 (en) | 2008-12-30 | 2012-09-25 | Case Western Reserve University | Photocrosslinked biodegradable hydrogel |
| JP2012514458A (ja) | 2008-12-31 | 2012-06-28 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗リンホトキシン抗体 |
| CN102325875B (zh) | 2009-01-08 | 2018-04-10 | 阿尔伯爱因斯坦医学有限公司 | 具有细胞壁结合神经酰胺类糖脂的细菌疫苗及其应用 |
| CN101829361B (zh) | 2009-03-10 | 2013-08-21 | 广州迈普再生医学科技有限公司 | 一种用于组织修复的纳米仿生材料及其制备方法 |
| JP2010227012A (ja) | 2009-03-27 | 2010-10-14 | Seiko Epson Corp | がん細胞捕捉デバイス |
| US9297005B2 (en) | 2009-04-13 | 2016-03-29 | President And Fellows Of Harvard College | Harnessing cell dynamics to engineer materials |
| US8551749B2 (en) | 2009-04-23 | 2013-10-08 | The Invention Science Fund I, Llc | Device including bone cage and method for treatment of disease in a subject |
| CN101584612B (zh) | 2009-06-12 | 2011-11-09 | 广州迈普再生医学科技有限公司 | 一种基于原位自体干细胞技术的再生型人工血管及其制备方法 |
| AU2010278702C1 (en) | 2009-07-31 | 2016-07-14 | Forsyth Dental Infirmary For Children | Programming of cells for tolerogenic therapies |
| CN101655611B (zh) | 2009-09-11 | 2011-06-08 | 中国科学院长春应用化学研究所 | 一种具有双层杂化结构的反蛋白石水凝胶光子晶体的制备方法 |
| CN102686606A (zh) | 2009-10-09 | 2012-09-19 | 阿纳福公司 | 结合il-23r的多肽 |
| CA2776954A1 (en) | 2009-10-09 | 2011-04-14 | Anaphore, Inc. | Combinatorial libraries based on c-type lectin domain |
| US20110207166A1 (en) | 2009-11-06 | 2011-08-25 | Sarah Rivkah Vaiselbuh | Human bone marrow microenvironments and uses thereof |
| CN102656119B (zh) | 2009-12-18 | 2015-11-25 | 花王株式会社 | 介孔二氧化硅颗粒的制造方法 |
| JP5603063B2 (ja) | 2009-12-21 | 2014-10-08 | 花王株式会社 | 複合シリカ粒子の製造方法 |
| SG10201503351RA (en) | 2010-01-19 | 2015-06-29 | Harvard College | Engineered Opsonin for Pathogen Detection and Treatment |
| LT2536764T (lt) | 2010-02-18 | 2018-10-25 | Ose Immunotherapeutics | Anti-cd28 humanizuoti antikūnai |
| WO2011103594A1 (en) | 2010-02-22 | 2011-08-25 | Le Labogroup Sas | Enclosing materials in natural transport systems |
| RU2012141952A (ru) | 2010-03-02 | 2014-04-10 | Кинг Абдулла Юнивесити Ов Сайенс Энд Текнолэджи | Наночастицы волокон оксида кремния с развитой поверхностью |
| JP5647669B2 (ja) | 2010-03-04 | 2015-01-07 | 地方独立行政法人東京都立産業技術研究センター | 多孔質シリカの製造方法 |
| US9610328B2 (en) | 2010-03-05 | 2017-04-04 | President And Fellows Of Harvard College | Enhancement of skeletal muscle stem cell engraftment by dual delivery of VEGF and IGF-1 |
| WO2011113436A1 (en) | 2010-03-15 | 2011-09-22 | Ferrosan Medical Devices A/S | A method for promotion of hemostasis and/or wound healing |
| US20110300186A1 (en) | 2010-04-14 | 2011-12-08 | Battelle Memorial Institute | Functionalized Nano- and Micro-materials for Medical Therapies |
| US20110256184A1 (en) | 2010-04-14 | 2011-10-20 | Battelle Memorial Institute | Non-ordered Mesoporous Silica Structure for Biomolecule Loading and Release |
| EP2569633B1 (en) | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| US9114100B2 (en) * | 2010-05-17 | 2015-08-25 | Duke University | Methods of treatment using ex vivo expansion of cord blood T cells |
| CA2798739A1 (en) | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| GB201009273D0 (en) | 2010-06-03 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel vaccine |
| WO2011163669A2 (en) | 2010-06-25 | 2011-12-29 | President And Fellows Of Harvard College | Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones |
| EP2593098A4 (en) | 2010-07-16 | 2014-02-05 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY |
| US8912322B2 (en) | 2010-07-29 | 2014-12-16 | University Of Georgia Research Foundation, Inc. | Aza-dibenzocyclooctynes and methods of making and using same |
| WO2012019049A1 (en) | 2010-08-04 | 2012-02-09 | Georgia Tech Research Corporation | Devices, systems, and methods for excavating cancer cells |
| CN103237885B (zh) | 2010-10-01 | 2016-01-20 | 纽约市哥伦比亚大学理事会 | 用于细胞归巢和脂肪形成的组合物和方法 |
| CN107648668B (zh) | 2010-10-06 | 2021-06-18 | 哈佛学院董事会 | 用于基于材料的细胞疗法的可注射的成孔水凝胶 |
| CN102000689A (zh) | 2010-10-13 | 2011-04-06 | 山东淄博山川医用器材有限公司 | 一种防止一次性注射器再次使用的装置 |
| US9603894B2 (en) | 2010-11-08 | 2017-03-28 | President And Fellows Of Harvard College | Materials presenting notch signaling molecules to control cell behavior |
| KR20130061748A (ko) | 2011-02-24 | 2013-06-11 | 엠파이어 테크놀로지 디벨롭먼트 엘엘씨 | 키 입력 에러 감소 |
| US10647959B2 (en) | 2011-04-27 | 2020-05-12 | President And Fellows Of Harvard College | Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation |
| US10045947B2 (en) | 2011-04-28 | 2018-08-14 | President And Fellows Of Harvard College | Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration |
| US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
| MX374963B (es) | 2011-04-29 | 2025-03-06 | Selecta Biosciences Inc | Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos. |
| EP2714073B1 (en) | 2011-06-03 | 2021-03-10 | President and Fellows of Harvard College | In situ antigen-generating cancer vaccine |
| US8609688B2 (en) | 2011-06-24 | 2013-12-17 | Arqule, Inc. | Substituted imidazopyridinyl-aminopyridine compounds |
| AU2012275390A1 (en) | 2011-06-28 | 2014-01-16 | Whitehead Institute For Biomedical Research | Using sortases to install click chemistry handles for protein ligation |
| AU2012284097B2 (en) | 2011-07-18 | 2017-08-03 | President And Fellows Of Harvard College | Engineered microbe-targeting molecules and uses thereof |
| EP2765997A4 (en) | 2011-10-14 | 2015-06-24 | Stc Unm | POROUS NANOPARTICLE-SUPPORTED LIPID DOUBLE LAYERS (PROTOCOLS) FOR THE TARGETED RELEASE BY TRANSDERMAL RELEASE AND USE METHOD THEREFOR |
| US20130145488A1 (en) | 2011-12-06 | 2013-06-06 | Iowa State University Research Foundation, Inc. | Mesoporous silica nanoparticles suitable for co-delivery |
| CN104411331B (zh) | 2012-01-13 | 2018-08-21 | 哈佛学院董事会 | 在结构聚合装置中tlr激动剂的控制传递 |
| AU2013231638B2 (en) * | 2012-03-16 | 2017-10-12 | Merck Patent Gmbh | Targeting aminoacid lipids |
| KR101416290B1 (ko) | 2012-03-20 | 2014-07-09 | 한국과학기술연구원 | 생물 직교성 무동 클릭 화학을 통한 나노입자의 생체내 표적화 방법 |
| DK2838515T3 (da) * | 2012-04-16 | 2020-02-24 | Harvard College | Mesoporøse siliciumdioxidsammensætninger til modulering af immunresponser |
| AU2013263349B2 (en) | 2012-05-17 | 2016-09-08 | Extend Biosciences, Inc | Carriers for improved drug delivery |
| CN104684546A (zh) | 2012-06-07 | 2015-06-03 | 哈佛大学校长及研究员协会 | 用于药物靶向的纳米疗法 |
| IN2014KN00920A (https=) | 2012-06-21 | 2015-10-09 | Compugen Ltd | |
| US20140072510A1 (en) | 2012-09-13 | 2014-03-13 | Northwestern University | Synthetic Scaffolds for Metastasis Detection |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| CN105209074A (zh) | 2012-10-20 | 2015-12-30 | 得克萨斯大学体系董事会 | 癌细胞陷阱 |
| JP2016500704A (ja) | 2012-11-06 | 2016-01-14 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 細胞シグナル伝達を変調するための組成物及び方法 |
| EP2972375A2 (en) | 2013-03-13 | 2016-01-20 | Creatics LLC | Methods and compositions for detecting pancreatic cancer |
| SG11201507883SA (en) | 2013-03-29 | 2015-10-29 | Sumitomo Dainippon Pharma Co Ltd | Wt1-antigen peptide conjugate vaccine |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| JP6649250B2 (ja) | 2013-05-21 | 2020-02-19 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 操作されたヘム結合性構成物およびその使用 |
| WO2014190229A1 (en) | 2013-05-24 | 2014-11-27 | President And Fellows Of Harvard College | Methods of isolating microorganisms and uses thereof |
| US20150094518A1 (en) | 2013-09-27 | 2015-04-02 | The Regents Of The University Of California | Modular polymer platform for the treatment of cancer |
| CA2929277C (en) | 2013-11-01 | 2018-01-16 | Yale University | Delivery vehicles comprising il-2 and losartan |
| US20170173212A1 (en) | 2014-03-27 | 2017-06-22 | Board Of Regents, The University Of Texas System | Compositions and methods for growing autologous biological tissue |
| ES2951908T3 (es) | 2014-04-04 | 2023-10-25 | Harvard College | Hidrogeles reticulados por química clic y métodos de uso |
| PL4023249T3 (pl) * | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| EP3137105A4 (en) | 2014-04-30 | 2017-12-27 | President and Fellows of Harvard College | Combination vaccine devices and methods of killing cancer cells |
| US11065362B2 (en) | 2014-06-12 | 2021-07-20 | President And Fellows Of Harvard College | Viscoelastic hydrogels with fast stress relaxation |
| US11229607B2 (en) | 2014-06-30 | 2022-01-25 | President And Fellows Of Harvard College | Hydrogel compositions comprising encapsulated cells and methods of use thereof |
| CN106687584B (zh) * | 2014-09-04 | 2021-08-13 | 干细胞技术公司 | 用于t细胞或nk细胞活化和扩增的可溶性抗体复合物 |
| CN104227191B (zh) | 2014-09-10 | 2016-04-20 | 北京工业大学 | 一种低背压穿透电弧焊接装置及方法 |
| US10357780B2 (en) | 2014-10-27 | 2019-07-23 | President And Fellows Of Harvard College | Magnetic capture of a target from a fluid |
| US11786457B2 (en) | 2015-01-30 | 2023-10-17 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| WO2016161372A1 (en) | 2015-04-01 | 2016-10-06 | President And Fellows Of Harvard College | Immunoconjugates for programming or reprogramming of cells |
| WO2016164705A1 (en) | 2015-04-10 | 2016-10-13 | Omar Abdel-Rahman Ali | Immune cell trapping devices and methods for making and using the same |
| EP3331549B1 (en) | 2015-08-06 | 2020-12-23 | President and Fellows of Harvard College | Improved microbe-binding molecules and uses thereof |
| KR20180058737A (ko) | 2015-10-07 | 2018-06-01 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 암 선택적 표지화 및 표적화를 위한 트리거-활성화 대사성 당 전구체 |
| EP3821880A1 (en) | 2015-10-26 | 2021-05-19 | President and Fellows of Harvard College | Oxidized polysaccharides and methods of use thereof |
| US11752238B2 (en) | 2016-02-06 | 2023-09-12 | President And Fellows Of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
| MA44252A (fr) | 2016-02-16 | 2018-12-26 | Harvard College | Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation |
| WO2017165464A1 (en) | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| EP3254684B1 (en) | 2016-06-08 | 2019-10-23 | Lysatpharma GmbH | Human platelet lysate or fraction enriched in human platelet-derived extracellular vesicles, for use in medicine |
| CN109789092A (zh) * | 2016-07-13 | 2019-05-21 | 哈佛学院院长等 | 抗原呈递细胞模拟支架及其制备和使用方法 |
| IL264557B2 (en) | 2016-08-02 | 2024-01-01 | Harvard College | Biological agents for regulating immune responses |
| JP6300289B1 (ja) | 2017-01-23 | 2018-03-28 | 株式会社サンセイアールアンドディ | 遊技機 |
| WO2018144966A1 (en) | 2017-02-06 | 2018-08-09 | The Board Of Trustees Of The Leland Stanford Junior University | Bioconjugation methods for targeted in situ therapeutic delivery |
| US11299509B2 (en) | 2017-02-10 | 2022-04-12 | The Board Of Trustees Of The University Of Illinois | Trigger-activatable sugar conjugates for cancer-selective labeling and targeting |
| US20210113466A1 (en) | 2017-03-16 | 2021-04-22 | Children's Medical Center Corporation | Non-viral, non-cationic nanoparticles and uses thereof |
| CA3063932A1 (en) | 2017-05-18 | 2018-11-12 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
| WO2018227205A1 (en) | 2017-06-09 | 2018-12-13 | President And Fellows Of Harvard College | Compositions for inducing an immune response |
| WO2020061129A1 (en) | 2018-09-19 | 2020-03-26 | President And Fellows Of Harvard College | Compositions and methods for labeling and modulation of cells in vitro and in vivo |
| CN113518635A (zh) | 2018-12-17 | 2021-10-19 | 哈佛学院院长等 | 用于调节免疫系统的生物工程化支架及其用途 |
| WO2021155297A1 (en) | 2020-01-29 | 2021-08-05 | President And Fellows Of Harvard College | Methods for labeling and targeting cells |
-
2017
- 2017-07-13 CN CN201780054844.6A patent/CN109789092A/zh active Pending
- 2017-07-13 EP EP17828455.0A patent/EP3484448B1/en active Active
- 2017-07-13 CN CN202210692354.1A patent/CN115404196A/zh active Pending
- 2017-07-13 ES ES17828455T patent/ES3032115T3/es active Active
- 2017-07-13 CN CN202210715468.3A patent/CN115537372A/zh active Pending
- 2017-07-13 MA MA045738A patent/MA45738A/fr unknown
- 2017-07-13 EP EP25169266.1A patent/EP4606890A3/en active Pending
- 2017-07-13 FI FIEP17828455.0T patent/FI3484448T3/fi active
- 2017-07-13 DK DK17828455.0T patent/DK3484448T3/da active
- 2017-07-13 WO PCT/US2017/041912 patent/WO2018013797A1/en not_active Ceased
- 2017-07-13 JP JP2019501623A patent/JP2019522486A/ja not_active Withdrawn
- 2017-07-13 CA CA3030427A patent/CA3030427A1/en active Pending
- 2017-07-13 AU AU2017295704A patent/AU2017295704B2/en active Active
- 2017-07-13 CN CN202210693172.6A patent/CN115305229B/zh active Active
- 2017-07-13 US US16/316,778 patent/US11555177B2/en active Active
-
2021
- 2021-10-14 JP JP2021168585A patent/JP7497054B2/ja active Active
-
2022
- 2022-11-30 US US18/072,449 patent/US20230340404A1/en active Pending
-
2023
- 2023-10-09 AU AU2023248053A patent/AU2023248053B2/en not_active Expired - Fee Related
-
2024
- 2024-03-25 JP JP2024047889A patent/JP7758384B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019522486A5 (https=) | ||
| Turtle et al. | Artificial antigen-presenting cells for use in adoptive immunotherapy | |
| CN113791208B (zh) | 用于识别、富集和/或扩增抗原特异性t细胞的试剂和方法 | |
| Li et al. | MART-1–specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro | |
| Xu et al. | Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens | |
| Kuball et al. | Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2. 1-specific TCR | |
| Dudley et al. | Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients | |
| Hinrichs et al. | Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy | |
| Monsurro et al. | Functional heterogeneity of vaccine-induced CD8+ T cells | |
| Castro et al. | The basis of distinctive IL-2–and IL-15–dependent signaling: Weak CD122-dependent signaling favors CD8+ T central-memory cell survival but not T effector-memory cell development | |
| JP7558151B2 (ja) | Ｔ細胞改変 | |
| Sonntag et al. | Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report | |
| Hervas-Stubbs et al. | CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy | |
| TW202110875A (zh) | 病毒載體及其在授受性細胞療法之應用 | |
| CN104159909A (zh) | 产生用于癌症治疗的t细胞持续性群体的组合物和方法 | |
| CN113677352A (zh) | T细胞修饰 | |
| US20250186586A1 (en) | Methods of isolating and enhancing populations of tumor-reactive lymphocytes | |
| IL312302A (en) | Methods for creating cells | |
| KR20200104283A (ko) | 적응 요법을 위한 항원-특이적 t 세포를 포함하는 세포 조성물 | |
| Adler et al. | Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation | |
| JP2023539056A (ja) | Ｔ細胞を製造する組成物および方法 | |
| Dissanayake et al. | Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvant | |
| van Belzen et al. | Immune biomarkers for predicting response to adoptive cell transfer as cancer treatment | |
| Jandus et al. | Tumor Antigen–Specific FOXP3+ CD4 T Cells Identified in Human Metastatic Melanoma: Peptide Vaccination Results in Selective Expansion of Th1-like Counterparts | |
| Lo Presti et al. | Use of cord blood derived T-cells in cancer immunotherapy: milestones achieved and future perspectives |